DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaFOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experienceRecent progress in pancreatic cancerChromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomasMolecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic CancerFAK and paxillin, two potential targets in pancreatic cancerNeoadjuvant radiotherapeutic strategies in pancreatic cancerAdjuvant therapy for pancreas cancer in an era of value based cancer careManagement of borderline resectable pancreatic cancerAdvances of stereotactic body radiotherapy in pancreatic cancerPerspectives in the treatment of pancreatic adenocarcinomaNeoadjuvant therapy for localized pancreatic cancer: guiding principlesPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesOrchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not DestructionAdvances in systemic therapy for advanced pancreatobiliary malignanciesMolecular landscape of pancreatic cancer: implications for current clinical trialsUnexpected gynecologic findings during abdominal surgeryEvolution and dynamics of pancreatic cancer progressionSelection criteria in resectable pancreatic cancer: a biological and morphological approachGenetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencingPancreatic adenocarcinoma: treating a systemic disease with systemic therapyHuman correlates of provocative questions in pancreatic pathologyCIViC databaseSMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.A current perspective on stereotactic body radiation therapy for pancreatic cancerNew challenges in perioperative management of pancreatic cancerAdvances in chemotherapy for pancreatic cancerPhase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerInhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation responseA Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.Distal pancreatectomy with celiac axis resection: what are the added risks?Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data BaseGenotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasisA phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
P2860
Q21129230-6D3763A5-9326-457A-84CC-99954C263AEDQ24622390-0A5D41D4-280F-4644-BA98-6C729CB4876EQ24626346-9F4235B7-9847-4C1C-B01F-91CC0171AC34Q26751724-31F9ADFE-3F97-494A-8147-E2DBB2B58C9DQ26765241-14D7E0D1-E023-4D6F-949E-758AEEFBA4E2Q26765360-17FBD619-62E9-4149-95FA-781304BCC2EAQ26766686-05E2466D-9CF5-4533-8B15-596BFB61DC80Q26775916-150C0205-692D-4907-9D98-A12B7D632956Q26781445-7FC9D9B4-A222-4413-BDDE-F6FA1125A2DEQ26781550-3D366945-C174-4359-BACB-D1432BCC4AF1Q26797248-685A068F-1292-4BBE-8D0A-807F5B64BB22Q26799428-48E49877-DA85-4856-AAB7-C40D38189A59Q26799714-F5BF2A45-8B0A-4421-ABD0-71FF90DF034EQ26801834-489E9628-0032-4850-BFCA-37D2C9D66FB5Q26822703-E85AE458-EAA5-4A3D-AC5A-1B3E52ABD78DQ26824528-09054ADA-E0FB-48EA-8CAD-86E0B06D519DQ26828571-50EA4A19-F8D8-4CE4-8ECD-546BE5B08DECQ26849671-102B27E8-6A5B-4B34-A4EB-BC56046D2402Q26859742-2DE24162-DA52-42DA-B5B7-00F013DF2791Q26991615-37BB9362-465E-4BD2-B3C0-BFBF528EC22DQ27008346-A9CECF6F-D23E-496C-AA3E-D96A3AB715F9Q27023576-9F0AD34E-D1E9-41DD-957C-99A8B35B3575Q27612411-F1E45D3B-4130-4902-9329-7DB0F21D6D11Q27851475-3068EB06-DBBB-4C17-82F9-53C471824BA7Q28077111-7CC945A4-C164-46CD-9693-40A5419EA432Q28082422-6536CBBF-0787-409D-8624-FF4B6FDD1603Q28085711-3873C4BA-95A6-4847-93FD-730479B44FBFQ28552089-4FF6F5CF-80D3-4026-AEDA-0B5D1D57CC4EQ28728326-30D62EC3-4105-428A-AD72-9B1CA23355D6Q30238706-53E01066-8989-41EB-94B5-3AFE769E2564Q30249814-01702C2A-FE11-4949-AB7B-3509F0E802AEQ30356819-D9FA528F-6356-41A2-8DD3-32FAC0EBA288Q30422607-381CCE00-AF0A-4CC5-B854-B7075BE38FA3Q30423279-61AE2291-ED07-4EA4-8C03-8F88C468F722Q30528894-D3AAE1D0-B3DD-4F16-8878-0AEF8ED12B40Q30726275-A0D90836-E448-4E76-B255-CD4B03E03708Q30754497-999378D9-4973-42F9-A4DE-2C13803A60DCQ30987695-95A20AAD-008D-42AF-8397-7DA3EDB75366Q31132024-6CA3D1E1-AA46-4931-8152-63F62DE12A61Q33400984-B8A57992-86E2-444E-A41A-8EE4A037CED8
P2860
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@ast
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@en
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@nl
type
label
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@ast
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@en
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@nl
altLabel
DPC4 Gene Status of the Primar ...... atients With Pancreatic Cancer
@en
prefLabel
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@ast
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@en
DPC4 gene status of the primar ...... tients with pancreatic cancer.
@nl
P2093
P2860
P50
P3181
P356
P1476
DPC4 gene status of the primar ...... atients with pancreatic cancer
@en
P2093
Alison P Klein
Charles J Yeo
Clark M Henderson
Daniel Laheru
Hisashi Abe
James R Eshleman
Jesse W Keller
John L Cameron
Joseph M Herman
P2860
P304
P3181
P356
10.1200/JCO.2008.17.7188
P407
P577
2009-03-09T00:00:00Z